BioDetego is developing, VASPfore, a new biomarker test for selecting cancer treatment protocols.
Business Model:
Revenue: $0
Employees: 1-10
Address: 3711 Market Street Suite 800
City: Philadelphia
State: PA
Zip: 19104
Country: US
BioDetego is developing, VASPfore, a new biomarker test for selecting cancer treatment protocols. The VASP marker provides information that will direct chemotherapy to high risk patients who will likely benefit from treatment while preventing costly and harmful treatment of low risk patients. BioDetego predicts that the VASPfore will provide payors enormous savings (&g;$150MM/year) by reducing total treatment costs. The company is led by David Zuzga, Ph.D., Founder and CEO, a research scientist with expertise in cell and molecular biology at La Salle University &a; Giovanni M. Pitari, M.D., Ph.D. Founder and CSO, a physician and research scientist with expertise in Translational Oncology.
Contact Phone:
+18567012453
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 5/2014 | Seed Round | 1 | - |
BioAdvance BioAdvance |
3/2014 | Seed Round | 1 | $50k |
Ben Franklin Technology Partners of Southeastern Pennsylvania Ben Franklin Technology Partners of Southeastern Pennsylvania |
5/2014 | Seed Round | 1 | - |
BioAdvance BioAdvance |
---|
Announced Date | Name | Price |
---|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|